Clinuvel Pharmaceuticals

Rising Healthcare Expenditure And Aging Population Will Drive SCENESSE Uptake

AnalystHighTarget

Not Invested

Community Contributor

Published

16 Jul 25

n/a

AnalystHighTarget's Fair Value

n/a

-16.6%

2.9%

-16.6%

2.9%

You can edit this narrative until Jul 16 9:12 PM. Then, changes will post as Updates.

Author's Valuation

AU$37.2570.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$37.25

70.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

22.04%

Biotech revenue growth rate

7.96%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.68%

Calculation

AU$164.76m

Earnings '28

13.65x

PE Ratio '28

AU$2.25b

Market Cap '28

AU$2.25b

Market Cap '28

50.29m

No. shares '28

AU$44.71

Share Price '28

AU$44.71 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$37.03

Fair Value '25